Article
The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes.
Diabetes care - 1 May 2005
Kang Eun Seok, Park So Young, Kim Hyeong Jin, Ahn Chul Woo, Nam Moonsuk, Cha Bong Soo, Lim Sung Kil, Kim Kyung Rae, Lee Hyun Chul
Abstract excerpt
OBJECTIVE: The aim of this study was to examine the effects of rosiglitazone on adiponectin and plasma glucose levels in relation with common adiponectin gene (ACDC) polymorphisms. RESEARCH DESIGN AND METHODS: A total of 166 patients with type 2 diabetes were treated with rosiglitazone (4 mg/day) for 12 weeks without changing any of their previous medications. In all, single nucleotide polymorphism (SNP)45 and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
